Tag: Endogenous GABA-A neurosteroid

Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one; 3alpha,5alpha-tetrahydroprogesterone; brexanolone) is an endogenous C21 pregnane neurosteroid biosynthesized from progesterone by sequential 5alpha-reductase and 3alpha-hydroxysteroid oxidoreductase activity in the central nervous system, adrenal cortex, ovary, and placenta. First isolated from adrenal tissue in 1938 and identified as a potent positive allosteric modulator of GABA-A receptors by Majewska and colleagues in 1986, allopregnanolone occupies a singular position in neuropsychopharmacology as the most potent endogenous modulator of inhibitory GABAergic neurotransmission. At low nanomolar concentrations, the compound allosterically enhances GABA-gated chloride currents at both synaptic (alpha-beta-gamma-containing) and extrasynaptic (alpha-beta-delta-containing) GABA-A receptor subtypes; at higher micromolar concentrations, it directly gates the chloride channel in the absence of GABA. The extrasynaptic receptor preference distinguishes allopregnanolone from benzodiazepines and underlies its characteristic anxiolytic, anticonvulsant, sedative-hypnotic, and antidepressant pharmacology.

The translational trajectory of allopregnanolone spans more than eight decades. Selye reported the anesthetic properties of pregnane steroids in 1941. Baulieu and colleagues proposed the “neurosteroid” concept in 1981 after demonstrating de novo brain synthesis independent of peripheral endocrine sources. Majewska et al. (1986) established the GABA-A receptor mechanism. Paul and Purdy (1992) coined “neuroactive steroid” to encompass synthetic analogs acting through non-genomic receptor modulation. The modern clinical program began at Sage Therapeutics, which developed an intravenous formulation of synthetic allopregnanolone (designated SAGE-547, later brexanolone) for postpartum depression (PPD). Two Phase 3 randomized, double-blind, placebo-controlled trials (Meltzer-Brody et al. 2018) demonstrated rapid, clinically meaningful, and sustained reductions in Hamilton Depression Rating Scale (HAM-D) scores following a 60-hour continuous intravenous infusion. The United States Food and Drug Administration approved brexanolone (Zulresso) in March 2019 as the first therapy specifically indicated for PPD, subject to a Risk Evaluation and Mitigation Strategy (REMS) program requiring inpatient administration with continuous pulse oximetry monitoring owing to the risks of excessive sedation and loss of consciousness.

A parallel clinical program led by Roberta Diaz Brinton at the University of Arizona has investigated allopregnanolone as a regenerative therapeutic for Alzheimer’s disease, grounded in preclinical demonstrations that the compound promotes hippocampal neural stem cell proliferation, neurogenesis, oligogenesis, and restoration of cognitive function in transgenic Alzheimer’s models and wild-type aged mice. A Phase 1b/2a multiple ascending dose trial (NCT02221622) in early Alzheimer’s disease reported safety, tolerability, and exploratory neuroimaging signals including preservation of hippocampal volume and functional connectivity changes after 12 weeks of intermittent intravenous dosing. Additional clinical investigations have evaluated allopregnanolone in fragile X-associated tremor/ataxia syndrome (FXTAS), status epilepticus, traumatic brain injury, and essential tremor.

The principal pharmacokinetic limitation of endogenous allopregnanolone is negligible oral bioavailability (less than 5 percent), necessitating intravenous, subcutaneous, or intramuscular administration. This limitation drove development of orally bioavailable synthetic analogs, most notably zuranolone (SAGE-217), a deuterated allopregnanolone analog approved by the FDA in August 2023 for PPD, and ganaxolone (3beta-methyl allopregnanolone), approved for seizures associated with CDKL5 deficiency disorder in March 2022. Allopregnanolone is metabolized by extra-hepatic non-CYP pathways, principally keto-reduction, glucuronidation, and sulfation, with an elimination half-life of approximately 9 hours after intravenous infusion, a volume of distribution of approximately 3 L/kg, and greater than 99 percent plasma protein binding. The compound is a controlled substance (Schedule IV in the United States). This monograph reviews the chemistry, biosynthesis, receptor pharmacology, pharmacokinetics, preclinical and clinical evidence base across all studied indications, sourcing and quality verification, reconstitution and handling, stack-interaction considerations, adverse-event profile, and a structured comparative assessment of five neurosteroid GABA-A receptor modulators against allopregnanolone on five competency standards.